How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.

Catherine M ViscoliBernard ZinmanDavid FitchettChristoph WannerEleuterio FerranniniMartin SchumacherClaudia SchmoorKristin OhnebergOdd Erik JohansenJyothis T GeorgeStefan HantelErich BluhmkiJohn M Lachin

Published in: Diabetes care (2017)

In this exploratory analysis from the EMPA-REG OUTCOME trial, changes in markers of plasma volume were the most important mediators of the reduction in risk of CV death with empagliflozin versus placebo.

Keyphrases

phase iii
study protocol
clinical trial
phase ii
open label
cardiovascular events
double blind
cardiovascular disease
depressive symptoms